← Human Trials & Peer-Reviewed Studies
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
Plain-language guide to NCT06934655: phase 3 randomized trial of Semaglutide, 150 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06934655
- Phase
- phase 3
- Status
- recruiting participants
- Start
- 2026-09-01
- Completion (planned or actual)
- 2030-11-01
- Participants
- 150 (estimated)
- Design
- randomized, single-blind, treatment
- Conditions studied
- Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered phase 3 trial tested Semaglutide.
It had two arms (groups): Standard Care (no intervention) and Early reinitiation (experimental).
Standard of care following bariatric surgery. No Reinitiation of obesity optimizing medications.
The registry classes the interventions as drug.
Who Took Part
Enrollment: 150 planned participants were the target.
It was open to people of any sex aged from 12 years up to 18 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Ages 12 to 18 years. Tanner stage 3 or higher. Be willing to have blood collected before and after surgical procedure at defined points. Be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver.
The full record lists 7 inclusion and 5 exclusion criteria; among the exclusions: refuse to comply with eligibility criteria.
How the Study Was Run
The set-up was randomized, parallel-group and single-blind.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The Semaglutide group and the comparison group ran side by side rather than switching.
In this single-blind Semaglutide study one party knew the assignments and the other did not.
Those kept unaware of assignments: outcomes assessor.
It started in 2026-09-01 with completion listed for 2030-11-01.
It ran at 1 site in United States.
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Percent Body Mass Index (time frame: From enrollment to the end of the end of the study at 24 months).
It also tracked 1 secondary outcome, for example Modified percent time in range.
What This Means in Plain Language
Put simply, this is a phase 3, randomized trial of Semaglutide in 150 people.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.